CCR8⁺ regulatory T cell depletion overcomes immune checkpoint blockade resistance in BRCA2-deficient prostate cancer

BRCA2-mutated prostate cancer is an aggressive, genomically unstable subtype, yet how this genomic instability influences tumor immunity remains undefined. We developed an isogenic, immunocompetent model of Brca2-deficient prostate cancer in which BRCA2 loss activated the cGAS/STING pathway and a type I interferon response across multiple cellular compartments, paradoxically leading to an overall immunosuppressed tumor microenvironment. Within this microenvironment, tumor-associated macrophages were interferon-responsive and expressed the CCR8 ligand Ccl8, and there was enrichment of immunosuppressive CCR8⁺ regulatory T cells (Treg). Anti-PD-1 monotherapy was ineffective and instead reinforced this immunosuppressive circuit, leading to expansion of CCR8⁺ Tregs. However, depletion of CCR8⁺ regulatory T cells overcame resistance to checkpoint blockade. Analysis of human BRCA2-mutated prostate cancer showed elevated CCR8 expression, supporting the translational relevance of the CCR8⁺ Treg axis as a potential therapeutic target in a disease largely refractory to immunotherapy.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-12
DOI
https://doi.org/10.64898/2026.11.11.765808
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

CCR8⁺ regulatory T cell depletion overcomes immune checkpoint blockade resistance in BRCA2-deficient prostate cancer

Elise Y. Cai, X. G. Zhu, Ramya Parameswaran, Morgan E. Diolaiti et al.
bioRxiv (Cold Spring Harbor Laboratory)
Cancer Immunotherapy and Biomarkers
preprint

CCR8⁺ regulatory T cell depletion overcomes immune checkpoint blockade resistance in BRCA2-deficient prostate cancer

Elise Y. Cai, X. G. Zhu, Ramya Parameswaran, Morgan E. Diolaiti, Kimberly A. Rickman, Alan Ashworth, Harish N. Vasudevan, Franklin W. Huang, Irena Sun, Christina Thai, Yingyue Li, Hanbing Song, Valentina Rossi, Nicole Ziper
preprint en

Abstract

BRCA2-mutated prostate cancer is an aggressive, genomically unstable subtype, yet how this genomic instability influences tumor immunity remains undefined. We developed an isogenic, immunocompetent model of Brca2-deficient prostate cancer in which BRCA2 loss activated the cGAS/STING pathway and a type I interferon response across multiple cellular compartments, paradoxically leading to an overall immunosuppressed tumor microenvironment. Within this microenvironment, tumor-associated macrophages were interferon-responsive and expressed the CCR8 ligand Ccl8, and there was enrichment of immunosuppressive CCR8⁺ regulatory T cells (Treg). Anti-PD-1 monotherapy was ineffective and instead reinforced this immunosuppressive circuit, leading to expansion of CCR8⁺ Tregs. However, depletion of CCR8⁺ regulatory T cells overcame resistance to checkpoint blockade. Analysis of human BRCA2-mutated prostate cancer showed elevated CCR8 expression, supporting the translational relevance of the CCR8⁺ Treg axis as a potential therapeutic target in a disease largely refractory to immunotherapy.

bioRxiv (Cold Spring Harbor Laboratory)
San Francisco VA Medical Center (US), University of California, San Francisco (US), Tempus Labs (United States) (US), UCSF Helen Diller Family Comprehensive Cancer Center (US)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon